CD163 and cancer: CD163 expression on the cancer cells has been demonstrated in 48% of breast cancer biopsies [141], 39% of bladder cancer biopsies [135], 23% of rectal cancer biopsies [142] and 20% of colorectal cancer biopsies [124].